Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement | Lexeo Therapeutics
Summary
Lexeo Therapeutics priced a public offering and concurrent private placement that should bring in about $135 million before expenses. The company sold common stock in the public offering and pre-funded warrants in the private placement. The deal is expected to close around October 20, 2025, subject to customary closing conditions. Lexeo plans to use the capital as a clinical-stage genetic medicine company advancing therapies for cardiovascular diseases.
Funding
Amount
$135.0M
Total raised
Date
October 16, 2025
Announcement date
Investors
Stifel, Nicolaus & Company, Leerink Swann & Company, Cantor Fitzgerald, Oppenheimer & Co., Baird Capital, Balyasny Asset Management
Lead investors
Company
lexeotx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected